Domino Printing says sales up as expected; strong in Asia, Europe 'more difficult'

Domino Printing Sciences plc (DNO.L) chairman Peter Byrom told the company's AGM today that trading in the first four months of the financial year was in line with the board's expectations.

"We continue to have strong demand for our products. Unit sales are well ahead of the comparative period last year and, as expected, we continue to experience price erosion in certain sectors", Mr Byrom (pictured) said.

Domino develops ink jets, one of the original world-beating technologies that kick started the Cambridge high tech cluster, and laser technologies that enable coding and printing solutions. Variable data such as bar codes and traceability codes are printed onto products in industries such as food, beverage and pharmaceutical.

"So far 2006 has seen good market conditions in Asia. Trading in Western Europe has been more difficult. Our recent acquisitions continue to perform well and are contributing positively to the results of the Group.

"We have increased our investment in new product development in 2006 and are positioned to launch a number of new products in the coming months. We are also investing in our capability to provide total product traceability systems to our customers."

The stock market view of Domino is that it is well managed by a conservative group of executives. Its shares were marginally up (by 0.25p) on the news to 268.50p, which values Domino at £296m. It is trading about the mid point of its range over the past 12 months.

23rd March 2006

Previous articles
Cyan wins strong orders in 1Q09; prospects for 2H09 ‘exciting’
Brady boosts profit, revenue in 1H09; says ‘well placed’ for growth
Autonomy’s releases first cloud-based web content archive solution
Babraham Bioscience ties up funding for Bioincubator with EEDA injection
MMI losses widen as R&D spend builds; reports solid research progress
Briefs: Sareum boosted by Johnson & Johnson contract extension; NXT’s flat speakers into another Citreon
Divestments, settlements boost Acambis 3Q profit; market okays new growth strategy
ANT sees progress in unpredictable IPTV sector; Market cheered by maiden result
Wellcome Trust invests £20m in Kymab to build UK biopharma
Prelude Trust's portfolio sheds 11%; Board orders investigation of options going forward
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • Psynova


Dr Sabine Bahn MD, PhD, MRCPsych
Founder


Psynova Ltd is a new company, established in 2005 by Dr Sabine Bahn MD, PhD, MRCPsych, and Prof Chris Lowe PhD of the University of Cambridge, for the commercial development and exploitation of novel biomarkers for neuropsychiatric disorders. Building on 12 years of research by Dr Bahn, Psynova has

[Psynova's profile]


Top20 Index




Currently: 161.56